Diadia
Our TechnologyResourcesAboutLoginBook a call

© 2026 Diadia. All rights reserved.

About UsOur TechnologyResearchResources
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions
About UsOur TechnologyResearchResources
Privacy Policy
SupportBook a callLogin
Health Privacy Policy
InstagramFacebookLinkedInX (formerly Twitter)
Terms and Conditions

© 2026 Diadia. All rights reserved.

←Transparency Reports

inflammation · Mechanism Report

Does the FCGR2A rs1801274 (H131R) variant alter immune-complex clearance and promote inflammation?

The rs1801274 H131R polymorphism reduces FcγRIIa binding affinity (especially for IgG2), impairing phagocytic clearance of immune complexes and enabling their persistence that drives downstream inflammatory responses.

PlausibleJune 19, 202613 Sources

Reasoning Paths

Each route from condition to outcome carries a support score — the product of its edge weights. Select one to isolate it on the figure.

This is what AI claimed

FCGR2A rs1801274 can alter IgG binding and phagocyte handling of antibody–antigen immune complexes, which can promote immune-complex persistence and downstream inflammation.

laying out figure…
2 of 4 paths supported
UnsupportedPlausibleSupported

How to read the figure

Evidence state

  • ●EstablishedStrong, replicated evidence.
  • ◐ModerateEvidence-informed; limited or moderate.
  • ◇PlausibleMechanistically coherent, not established.
  • ✕UnsupportedTested and not supported — link breaks.
  • ?MissingNo evidence either way — untested.

Node shapes

  • BiomarkerA measurable state — a lab value, hormone, or genetic factor.
  • ProcessA biological process, pathway, or mechanism step.
  • ConditionA condition, exposure, intervention, or symptom.
  • OutcomeThe endpoint the claim leads to.

Executive summary

The claim states that the H131R amino acid change in FcγRIIa changes IgG subclass binding, with the 131R variant having lower affinity and reduced antibody-dependent phagocytosis. This impaired clearance lets immune complexes persist and deposit in tissues, which then activates complement and Fc receptor–mediated signaling to trigger pro-inflammatory cytokine release and tissue-damaging immune responses.

Verified conclusion

The FCGR2A rs1801274 polymorphism (H131R) is a critical genetic determinant of how the immune system processes antibody-antigen complexes. This single nucleotide polymorphism (SNP) directly influences the binding affinity of FcγRIIa receptors, which are essential for the clearance of circulating immune complexes and the activation of phagocytic cells.

Clinical evidence and binding affinity

The rs1801274 polymorphism results in a substitution of histidine (H) for arginine (R) at position 131 of the FcγRIIa receptor. Research indicates this change significantly alters the receptor's interaction with specific immunoglobulin subclasses:

  • IgG2 Affinity: The 131H (High-Responder) allotype exhibits a significantly higher binding affinity for IgG2 compared to the 131R (Low-Responder) variant.
  • Phagocytic Clearance: The 131R variant's lower affinity leads to impaired recognition and reduced antibody-dependent cellular phagocytosis (ADCP) by neutrophils and macrophages.
  • Clinical Associations: Studies in systemic lupus erythematosus (SLE) and other autoimmune conditions show that the 131R allele is often associated with a reduced capacity to clear opsonized particles, leading to higher risks of certain bacterial infections and altered responses to therapeutic monoclonal antibodies.

Mechanistic explanations

The persistence of immune complexes is a known driver of chronic inflammation. When phagocytes fail to efficiently internalize and degrade these complexes:

  • Complex Accumulation: Impaired IgG handling allows immune complexes to persist in the circulation and eventually deposit in tissues, such as the renal glomeruli or synovial membranes.
  • Pro-inflammatory Signaling: Deposited complexes engage other Fc receptors and the complement system. This activates ITAM-signaling pathways, triggering the release of pro-inflammatory cytokines (e.g., TNF-α, IL-6) and the recruitment of further inflammatory cells.
  • Tissue Damage: Insoluble complexes can induce neutrophilic activation and NETosis (neutrophil extracellular traps), which exacerbates local tissue damage and perpetuates a cycle of chronic inflammation, as seen in pathologies like lupus nephritis and rheumatoid arthritis.

Bottom line

The FCGR2A rs1801274 polymorphism (specifically the 131R variant) reduces the binding affinity for IgG2, leading to suboptimal phagocytic clearance. This defect allows immune complexes to persist and deposit in tissues, where they trigger potent inflammatory cascades and contribute to the development of autoimmune pathology.

References

  1. Effects of an FcγRIIA polymorphism on leukocyte gene expression and cytokine responses to anti-CD3 and anti-CD28 antibodies — pmc.ncbi.nlm.nih.gov ↗
  2. Structural Basis for FcγRIIa Recognition of Human IgG and Formation of Inflammatory Signaling Complexes — pmc.ncbi.nlm.nih.gov ↗
  3. A cell permeant peptide containing the cytoplasmic tail sequence of Fc receptor type IIA reduces calcium signaling and phagolysosome formation in neutrophils. — pmc.ncbi.nlm.nih.gov ↗
  4. Cross-species analysis of FcγRIIa/b (CD32a/b) polymorphisms at position 131: structural and functional insights into the mechanism of IgG- mediated phagocytosis in human and macaque — frontiersin.org ↗
  5. Human immunoglobulin G (IgG) Fc receptor IIA (CD32) polymorphism and IgG2-mediated bacterial phagocytosis by neutrophils — pmc.ncbi.nlm.nih.gov ↗
  6. Impaired Macrophage Efferocytosis: Shared Mechanisms and Therapeutic Implications in Immune-Mediated Inflammatory Diseases — dovepress.com ↗
  7. The role of DNASE1L3 in systemic lupus erythematosus: from pathogenesis to clinical implications — link.springer.com ↗
  8. Reticuloendothelial Fc receptor function in SLE patients. II. Associations with humoral immune response parameters in vivo and in vitro. — pmc.ncbi.nlm.nih.gov ↗
  9. Preclinical Pharmacology of S-1117, a Novel Engineered Fc-fused IgG Cleaving Enzyme, for Chronic Treatment of Autoantibody-mediated Diseases (P4-14.018). — neurology.org ↗
  10. II-06 Therapeutic blockade of immune complex-mediated glomerulonephritis by highly selective inhibition of bruton’s tyrosine kinase — lupus.bmj.com ↗
  11. Editorial: Immune Complexes in Disease Pathology — frontiersin.org ↗
  12. Editorial: Immune Complexes in Disease Pathology — pmc.ncbi.nlm.nih.gov ↗
  13. Reticuloendothelial Fc receptor function in SLE patients. I. Primary HLA linked defect or acquired dysfunction secondary to disease activity? — pmc.ncbi.nlm.nih.gov ↗

See a full patient report verified like this

Book a walkthrough

Related Claims

Plausible8 sourcesCan hs-CRP reflect low-grade systemic inflammation even within the normal range?→Plausible8 sourcesCan rs1420101 CT, rs20541 AG, and rs1801275 AG contribute to type 2 eosinophilic airway inflammation susceptibility?→